Previous 10 |
HONOLULU , Nov. 14, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced results for the third quarter of 2019. Highlights were as follows: CHASE Clinical Trial . On September 23, 2019 , the Company announced results from the pre-specified interim review of its ongoing CHAS...
HONOLULU , Sept. 23, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) today announced results from the pre-specified interim review of its ongoing CHASE ( C ardiovascular H ealth A staxanthin S upplement E valuation) clinical trial. The CHASE clinical trial is a double-blind, random...
Cardax ( OTCQB:CDXI ): Q2 GAAP EPS of -$0.01. More news on: Cardax, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
HONOLULU , Aug. 14, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) today filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 . Recent developments include: CHASE Clinical Trial Update Cardax plans a pre-specified interim review in September 2019 o...
HONOLULU , Aug. 14, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced today that it filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed follow-on public offering of up to $15 million of the Company's common stock and warra...
HONOLULU , May 17, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced results for the quarter ended March 31, 2019 , in its Quarterly Report on Form 10-Q filed May 15, 2019 with the SEC. Cardax continued to make progress in Q1 2019 across its primary areas of focus: the ZanthoS...
HONOLULU , March 28, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced results for the year ended December 31, 2018 , in its Annual Report on Form 10-K filed today with the SEC. Highlights: ZanthoSyn® Sales . Revenues from Cardax's ZanthoSyn®, a physician reco...
HONOLULU , Jan. 25, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI), a life sciences company focused on inflammatory health, today announced that its CEO, David G. Watumull , will present at NobleCon XV—Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hote...
News, Short Squeeze, Breakout and More Instantly...
Cardax Voluntarily Suspends SEC Reporting Obligations Expected savings to support core business strategies PR Newswire HONOLULU , Aug. 11, 2021 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced today the filing of a Form 15 with the U.S. Securities and...
Cardax Reports Q1 2021 Results - Operating loss decreased vs. Q1 2020 - Net loss increased vs. Q1 2020 - ZanthoSyn® revenues decreased vs. Q1 2020 - Company pursuing multiple funding opportunities PR Newswire HONOLULU , May 14, 2021 /PRNewswi...
Cardax Reports 2020 Results - Net loss and operating expenses decreased vs. 2019 - ZanthoSyn® revenues decreased vs. 2019 - Company pursuing multiple funding opportunities - CHASE study recruitment suspended due to COVID-19 - COVID-19 clinical trial grant ap...